1/PD-1 #biology has had a renaissance in recent years

#Immunology

🧵

Schematic from "A Cure Within" ISBN 1621822176 p.33
2/Let me get back in history for one tweet.

Basically, PD-1 KO mice do not have the dramatic proinflammatory lethal phenotype of CTLA-4 KO

So it was hard to predict that this molecule has any future as a therapeutic intervention, let alone a bigger promise than CTLA-4
3/ What's the mechanism?

It remained complicated for a while (and remains so in my opinion)

For example, the early epiphany by Barber et al. showed that PD-1 blockade restored T cell effector function in chronic LCMV infection ➡️ https://rdcu.be/cjx3X 
4/ But this seminal study showed reversal of exhaustion at the "population" level so it did not definitively show a restoration of function of the "already exhausted" T cells per se

(I hope this tweet is clear, I feel like I opsonized myself for phagocytic responses)
6/ To add to our confusion, Wherry and co. that PD-1 deficiency ENHANCES T cell exhaustion

➡️ https://rupress.org/jem/article/212/7/1125/41837/Genetic-absence-of-PD-1-promotes-accumulation-of
7/ So...We know that PD-1 blockade has a clinical therapeutic benefit in T cell responses

Again, what's the mechanism?
8/ Several interesting recent answers:

First, H. Chang and M. Davis' groups showed that PD-1 blockade did not reinvigorate exhausted T cells but promoted the expansion of new tumor-specific T cell clones

➡️ https://www.nature.com/articles/s41591-019-0522-3

This was a defining moment in the field
9/ Thanks to paired scTCR sequencing and GE
10/ An equally important discovery was made by @SamirNKhleif's group showing that PD-1 blockade in the absence of optimal T cell stimulation (e.g. vaccine, inflammation...etc) leads to worse outcomes than no blockade

➡️ https://www.nature.com/articles/s41590-019-0441-y
12/ All stressing the fact that you need optimal T cell priming and response before you block PD-1
13/ Last but not least, V. Boussiotis and co. showed [surprisingly] that PD-1 deletion on myeloid cells promotes antitumor immunity, upending the paradigm that the impact of PD-1 blockade is primarily T cell-mediated.

➡️ https://immunology.sciencemag.org/content/5/43/eaay1863
14/ Therefore, PD-1 leads more than a double life as a regulatory protein and we are likely to discover more roles.

And will keep adding to this drawing

"A Cure Within" p.35 -Tasuko Honjo
You can follow @Plasmacellguy.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled: